A randomized controlled trial of visible-light therapy for the prevention of XXXX .

@entity1 @entity33 @entity3136 @entity158
The objective of this study was to assess the efficacy of a novel visible-light therapy (VLT) device for the prevention of @entity3136 in hematopoietic stem cell transplantation (HSCT) @entity1 . A VLT-device suitable for intra-oral use was applied to 20 @entity1 undergoing HSCT. The study design was placebo-controlled, randomized and double-blind. @entity3136 was assessed using the OMAS and WHO scales. @entity158 and acceptance levels were scored by the @entity1 using a 10-step scale. @entity1 were evaluated once a week until day 21 post-HSCT. @entity33 rate, severity and @entity158 score were compared. At the third visit, 1week post-HSCT, @entity33 rates were significantly lower in the treatment group (for both WHO and OMAS p=0.02). @entity33 was also less severe in the treatment group (for WHO p=0.01; for OMAS p=0.01). Furthermore, the @entity1 in the treatment group reported @entity158 levels (p=0.04). The treatment was well tolerated and highly accepted, with no reports of adverse events related to the device. These findings suggest that the VLT-device is safe and effective for the prevention of @entity3136 in @entity1 undergoing HSCT.
